Potent, competitive, transportable EAAT1-4 inhibitor/non-transportable EAAT5 inhibitor. Also available as part of the Excitatory Amino Acid Transporter Inhibitor Tocriset™.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|phosphate buffered saline||15.91||100|
Preparing Stock Solutions
The following data is based on the product molecular weight 159.14. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||6.28 mL||31.42 mL||62.84 mL|
|5 mM||1.26 mL||6.28 mL||12.57 mL|
|10 mM||0.63 mL||3.14 mL||6.28 mL|
|50 mM||0.13 mL||0.63 mL||1.26 mL|
References are publications that support the products' biological activity.
Bridges et al (1991) Conformationally defined neurotransmitter analogues. Selective inhibition of glutamate uptake by one pyrrolidine-2,4-dicarboxylate diastereomer. J.Med.Chem. 34 717 PMID: 1671706
Mitrovic and Johnston (1994) Regional differences in the inhibition of L-glutamate amd L-aspartate sodium-dependent high affinity uptake systems in rat CNS synaptosomes by L-trans-pyrrolidine-2,4-dicarboxylic threo-3-hydroxy-D-aspartate and D-aspartate. Neurochem.Int. 24 583 PMID: 7981641
Zuiderwijk et al (1996) Effects of uptake carrier blockers SK & F 89976-A and L-trans-PDC on in vivo release of amino acids in rat hippocampus. Eur.J.Pharmacol. 307 275 PMID: 8836615
If you know of a relevant reference for L-trans-2,4-PDC, please let us know.
View Related Products by Product Action
Keywords: L-trans-2,4-PDC, supplier, potent, competitive, Transportable, EAAT1-4, EAAT2, EAAT3, EAAT4, inhibitors, inhibits, non-transportable, EAAT5, EAAT, Excitatory, Amino, Acid, Transporters, GLAST, GLT-1, Glutamate, Monoamine, Neurotransmitter, reuptake, trans-4-Carboxy-L-proline, Glutamate, Transporters, Glutamate, Transporters, Tocris Bioscience
4 Citations for L-trans-2,4-PDC
Citations are publications that use Tocris products. Selected citations for L-trans-2,4-PDC include:
Young et al (2007) Glutamate receptor expression and chronic glutamate toxicity in rat motor cortex. PLoS One 26 78 PMID: 17240155
Yin and Weiss (2012) Marked synergism between mutant SOD1 and glutamate transport inhibition in the induction of motor neuronal degeneration in spinal cord slice cultures. Brain Res 1448 153 PMID: 22370146
Heinrich et al (2012) K+ depolarization evokes ATP, adenosine and glutamate release from glia in rat hippocampus: a microelectrode biosensor study. Br J Pharmacol 167 1003 PMID: 22394324
Beaulé et al (2009) Circadian modulation of gene expression, but not glutamate uptake, in mouse and rat cortical astrocytes. PLoS One 4 e7476 PMID: 19829696
Do you know of a great paper that uses L-trans-2,4-PDC from Tocris? If so please let us know.
Reviews for L-trans-2,4-PDC
There are currently no reviews for this product. Be the first to review L-trans-2,4-PDC and earn rewards!
Have you used L-trans-2,4-PDC?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.